Navigation Links
AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
Date:4/8/2013

Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy.

"Basically what we're trying to do is use triple-negative breast cancer models to develop targeted drugs for treatment. Paragazole is an especially exciting candidate," says Jennifer Diamond, MD, investigator at the University of Colorado Cancer Center and medical oncologist at the University of Colorado Hospital.

Paragazole is a novel histone deacetylase (HDAC) inhibitor developed at CU Boulder in the laboratories of Xuedong Liu and Andy Phillips, being tested at the CU Cancer Center. In this study, Diamond and colleagues tested the drug against a range of breast cancer cell lines with and without combination with chemotherapies paclitaxel, gemcitabine or carboplatin. Interestingly, it was specifically the cell lines that didn't express estrogen the aggressive, triple-negative cells that were most affected by paragazole. Sure enough, the researchers saw increased expression of CARM1 mediated estrogen receptors in these especially sensitive cells.

It was as if paragazole set up these triple negative cells so that chemotherapy could be more effective.

"This really is a case in which the result was greater than the sum of its parts. Paragazole with chemotherapy was more effective than the combined effects of both drugs, alone," Diamond says.

Studies with the drug are continuing with the eventual goal of moving the therapy from the lab to the clinic in selected patients.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Page: 1

Related biology news :

1. REACH news: European ombudsman takes up PETA complaint
2. Good news: Fewer maternal and child deaths
3. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
4. Preclinical studies use specialized ultrasound to detect presence of cancer
5. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
6. Cleverly designed vaccine blocks H5 avian influenza in models
7. Pig brain models provide insights into human cognitive development
8. Engineering control theory helps create dynamic brain models
9. Mentoring models to move minorities to majorities in STEM
10. Transplanted neural stem cells slows als onset and progression in mouse models
11. Improving the development of new cancer models using an advanced biomedical imaging method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Business Development, Europe. Based in Paris, he will focus on acquiring new accounts ... are being met. , “Fred brings to our European clients more ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/8/2016)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... technology companies in the TSX Venture 50 TM . ... the TSX Venture Exchange, in each of five major industry ... & life sciences, diversified industries and technology – based on ... investment, market cap growth, trading volume and analyst coverage. All ...
Breaking Biology Technology: